Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test;Evaluación de la eficacia y del impacto clínico de la PET-18F-FDG en el diagnóstico de recurrencia del carcinoma medular de tiroides con calcitonina elevada y pruebas de imagen negativas

Revista Espanola de Medicina Nuclear e Imagen Molecular

Volumn 31, Issue 5, 2012, Pages 261-266

  Gomez Camarero P ^a   Ortiz de Tena, A ^a   Borrego Dorado, I ^a   Vazquez Albertino R J ^a   Navarro Gonzalez E ^a   Ruiz Franco Baux, J V ^a   Cuenca Cuenca, J I ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

18F FDG; Calcitonin; Medullary thyroid cancer; Metastases; PET; PET CT

Indexed keywords

CALCITONIN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; THYROID MEDULLARY CARCINOMA;

BONE NEOPLASMS; CALCITONIN; CARCINOMA, MEDULLARY; DISEASE PROGRESSION; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR MARKERS, BIOLOGICAL;

EID: 84865378827     PISSN: 2253654X     EISSN: 22538070     Source Type: Journal    
DOI: 10.1016/j.remn.2011.05.010     Document Type: Article

References (19)

1. Giraudet A.L., Vanel D., Leboulleux S., Aupérin A., Dromain C., Chami L., et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007, 92:4185-4190.
2. 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007, 48:501-507.
3. Khan N., Oriuchi N., Higuchi T., Endo K. Review of fluorine-18-2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Control cancer 2005, 12:254-260.
4. Rendl G., Manzl M., Hitzl W., Sungler P., Pirich C. Long-term prognosis of medullary thyroid carcinoma. Clin Endocrinol 2008, 69:497-505.
5. Cheung K., Roman S.A., Wang T.S., Walker H.D., Sosa J.A. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a costeffectiveness and decision analysis. J Clin Endocrinol Metab 2008, 93:2173-2180.
6. Elisei R., Bottici V., Luchetti F., Di Coscio G., Romei C., Grasso L., et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004, 89:163-168.
7. Costante G., Meringolo D., Durante C., Bianchi D., Nocera M., Tumino S., et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007, 92:450-455.
8. 18F-FDG PET Detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002, 43:66-71.
9. 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: A prospective study. Eur J Surg Oncol 2008, 34:581-586.
10. Vierhapper H., Raber W., Bieglmayer C., Kaserer K., Weinhäusl A., Niederle B. Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 1997, 82:1589-1593.
11. Brandt-Mainz K., Müller S.P., Görges R., Saller B., Bockisch A. The value of 18fluorine fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000, 27:490-496.
12. Gasparoni P., Rubello D., Ferlin G. Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma. J Endocrinol Invest 1997, 20:527-530.
13. Musholt T.J., Musholt P.B., Dehdashti F., Moley J.F. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Surgery 1997, 122:1049-1060.
14. Adams S., Baum R., Rink T., Schumm-Dräger P.M., Usadel K.H., Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998, 25:79-83.
15. Diehl M., Risse J.H., Brandt-Mainz K., Dietlein M., Bohuslavizki K.H., Matheja P., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicenter study. Eur J Nucl Med 2001, 28:1671-1676.
16. 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 2004, 11:786-794.
17. Oudoux A., Salaun P.Y., Bournaud C., Campion L., Ansquer C., Rousseau C., et al. Sensitivity and prognostic value of positron emission tomography with F-18-Fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab 2007, 92:4590-4597.
18. Elisei R. Routine serum calcitonin measurement in the evaluation of thyroid nodules. Best Practice and Research Clinical Endocrinology and Metabolism 2008, 22:941-953.
19. Marzola M.C., Pelizzo M.R., Ferdeghini M., Toniato A., Massaro A., Ambrosini V., et al. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging. Eur J Surg Oncol 2010, 36:414-421.